Our People

Management & Operations

Vlad Coric, M.D., Chairman & Chief Executive Officer

Vlad Coric, M.D.

Chairman & Chief Executive Officer

X

Vlad Coric, M.D.

MEET OUR CEO

In his over seven years as CEO of Biohaven, Dr. Coric led the company in the pursuit of its bold vision from an entrepreneurial start-up into a modern, publicly traded company listed on the New York Stock Exchange with the mission of advancing novel medications to underserved patients. His leadership translated into dramatic growth for the company, from its initial pre-money valuation of about $6M to the sale of the company for $13B in total considerations. Dr. Coric successfully led the company through its first FDA approval and the launch of Nurtec® ODT (rimegepant; CGRP receptor antagonist) for the acute treatment of migraine. A little more than one year later, Biohaven transformed the migraine treatment paradigm with the FDA approval of an expanded indication for Nurtec ODT for the preventive treatment of episodic migraine — becoming the first all-in-one migraine medication for the acute and preventive treatment of migraine. Biohaven also received approval in Europe and other major markets — advancing its “treat and prevent” migraine therapy to the approximately one billion patients suffering from migraine across the world. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. Capitalizing on the extraordinary patient and shareholder value that Biohaven has built with Nurtec ODT and its CGRP franchise, Dr. Coric spearheaded the acquisition of Biohaven by Pfizer in May 2022 for approximately $13 billion in total consideration.

Dr. Coric has positioned Biohaven on its new course continuing its growth trajectory, harnessing its proven drug development expertise, extensive portfolio of clinical-stage assets and robust discovery research capabilities. The pillars of the company’s success — Commitment to Patients, Winning with Science and Creating Shareholder Value — continue to be the foundation of Biohaven’s ongoing growth.

Under Dr. Coric’s stewardship, Biohaven has focused on discovering, developing and commercializing life-changing therapies that address unmet medical needs. The company’s focus on scientific innovation is evidenced in its broad therapeutic portfolio comprised of early- and late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, with little or no treatment options. These include epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA). In February 2022, Dr. Coric led Biohaven’s acquisition of a novel Kv7 channel targeting platform — adding the latest advances in ion-channel modulation to Biohaven’s neuroscience portfolio.

A proponent of innovation that extends beyond the R&D cycle to all aspects of pharmaceutical operations, Dr. Coric has been instrumental in establishing Biohaven’s agile, digital-centric operating and commercial model. Today, Biohaven is an industry leader in the use of digital tools and technologies to increase patient engagement and enhance the success of its novel treatments. Dr. Coric has also led the expansion of Biohaven to international markets, including the formation of subsidiaries in Ireland and Asia-Pacific.

Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. During his career, he has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec ODT (rimegepant; oral calcitonin related peptide antagonist), zavegepant (intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor), and Sunvepra® (asunaprevir; NS3 inhibitor).

Since July 2001, Dr. Coric has also continued to serve as an Associate Clinical Professor of Psychiatry at Yale School of Medicine. He previously served as the inpatient chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society. Dr. Coric has authored more than 65 peer-reviewed publications. Dr. Coric completed his internship at Yale-New Haven Hospital and residency training at the Yale Psychiatry Residency Training Program, where he also served as the program-wide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD service at the West-Haven Connecticut Veterans Administration Hospital.

Dr. Coric earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree. He was named one of the Top 25 Healthcare Technology Leaders of Connecticut for 2022 by The Healthcare Technology Report. He was the recipient of the Ernst & Young Entrepreneur of the Year 2018 Award in the New York region.

Matthew Buten, Chief Financial Officer

Matthew Buten

Chief Financial Officer

X

Matthew Buten

Matt has more than 20 years of experience in healthcare investing and more than 15 years as an advisor in investment banking, structuring deals for both small and large capitalization companies. From 2012 to 2021, he was a Managing Director at Foresite Capital, a dedicated healthcare venture and growth equity fund. He served many roles during his nine years at Foresite, including opening their NY office, sourcing and helping manage public and private investments, developing and maintaining relationships with Wall Street banking, research and sales and participating in the Investment Committee.

Prior to that, he was a healthcare portfolio manager at Catapult/Millennium Partners focused on U.S. healthcare services, medical technology, life science tools, big pharmaceutical, and specialty pharmaceutical companies. While at Millennium, Matt managed $400-600 million in combined long/short market neutral capital. Prior to joining Millennium, he was co-founder and co-manager of Sapphire Capital, where he focused on medical technology, diagnostics, life science tools suppliers, diagnostic services, and healthcare information technology.

Matt started his career as an investment banking associate focused on mergers and acquisitions, equity and debt financings and spin-offs. He spent 10 years at Smith Barney as a Director in Investment Banking before becoming Managing Director and Head of Healthcare Investment Banking for Needham and Company. While at Needham, he sourced healthcare venture capital opportunities for their venture capital fund, Needham Capital Partners. After that, Matt was an equity analyst at Argus Partners, a $1 billion healthcare fund where he focused on medical technology, life science tools and diagnostics and specialty services (PBMs). Matt graduated from The Wharton School at the University of Pennsylvania with a BS in economics.

Cliff Bechtold, M.S., President & General Manager, Biohaven Ireland, Chief Compliance Officer

Cliff Bechtold, M.S.

President & General Manager, Biohaven Ireland, Chief Compliance Officer

X

Cliff Bechtold, M.S.

Cliff is a 27-year veteran of the Pharmaceutical industry with a broad drug development experience and a track record of optimizing organizations and capabilities. Prior to joining Biohaven, Cliff was the Development Lead for Genetically Defined Diseases at Bristol-Myers Squibb Company (BMS). In this role he led the teams which developed innovative strategies and executed on two novel programs in neuromuscular and neurodegenerative diseases. In addition to these disease areas, Cliff has in-depth experience in all stages of program advancement from discovery to launch in diverse disease areas including virology, oncology, immunology, cardiovascular and neuroscience. This includes key leadership roles for the development and launch of Reyataz® and Sprycel®. At BMS, he also served as Head of Biologics Strategy and Operations with a key role in optimizing the company’s biologics development and manufacturing capabilities. As the Head of Strategic Operations at Adnexus Therapeutics, Cliff oversaw the organizational optimization and strategic integration. Through his career, Cliff has held multiple positions in Discovery, Clinical Development and leadership roles in Project Planning and Management. Cliff is currently serving as a member of the TREAT-NMD Advisory Committee for Therapeutics (TACT), ImagingDMD scientific advisory board and consults for Project Parent Muscular Dystrophy (PPMD). Cliff holds a Master of Science degree in Medical Microbiology from Creighton University School of Medicine and a Bachelor of Science degree from South Dakota State University.

Kimberly Gentile, Senior Vice President, Clinical Operations

Kimberly Gentile

Senior Vice President, Clinical Operations

X

Kimberly Gentile

Ms. Gentile has 30 years of experience in the pharmaceutical industry in all phases of clinical research from Phase 1 through Phase 4, predominantly in the areas of psychiatry and neurology. She has deep, hands-on experience in most key operational aspects of drug development, having held positions at small biotechnology companies, contract research organizations, investigative sites as well as small and large pharmaceutical companies. Prior to joining Biohaven in 2014, Ms. Gentile spent 14 years in the Clinical Operations group at Bristol-Myers Squibb where she was responsible for operational oversight of large-scale global programs in the areas of psychiatry and neurology, including the management of complex global programs in Anxiety Disorders, Treatment Resistant Depression and Alzheimer’s Disease. She has a proven track record of successfully managing complex and challenging drug development programs within set timelines and budgets.

Irfan Qureshi, M.D., Chief Medical Officer

Irfan Qureshi, M.D.

Chief Medical Officer

X

Irfan Qureshi, M.D.

Irfan is a Board-certified neurologist and physician-scientist who brings 13 years of industry and academic experience to Biohaven from Bristol-Myers Squibb and the Albert Einstein College of Medicine, including early and late stage clinical development, translational research, and patient care. At BMS, he served as clinical lead for several small molecule and biologic compounds targeting rare disease indications. Irfan propelled the BMS-986168/BIIB092 anti-tau antibody development program in Progressive Supranuclear Palsy from Phase 1 into a global registrational trial (PASSPORT Study). This innovative program was licensed from BMS to Biogen in 2017. Irfan continues to hold appointments of Clinical Assistant Professor in the Departments of Neurology and Medicine at Einstein where he conducted translational research on neurological and psychiatric disorders with an emphasis on emerging technology platforms (epigenetics, non-protein-coding RNAs, and stem cells and regenerative medicine); and also served as an investigator in clinical trials evaluating a spectrum of novel diagnostics, small molecule and biological therapeutics, and medical devices.

Irfan has a deep interest in biomedical technology innovation and has served as an advisor to early stage companies, investors, and university technology transfer offices (i.e., Einstein, Burke Research Institute, SUNY Downstate Medical Center). Prior to medical school, he was an associate at Anthem Capital Management, a venture capital firm. Irfan completed his neurology training and earned his M.D. from Einstein (Hunt Scholar). He also holds a B.S. in Biomedical Engineering from Johns Hopkins University (Goldwater Scholar). He has published more than 35 articles and book chapters, in leading journals such as Nature Reviews Neuroscience, the Proceedings of the National Academy of Sciences, and Trends in Neurosciences.

Bruce D. Car, DVM*, MVS, PhD, DACVP, Chief Scientific Officer

Bruce D. Car, DVM*, MVS, PhD, DACVP

Chief Scientific Officer

X

Bruce D. Car, DVM*, MVS, PhD, DACVP

Dr. Car joined Biohaven on August 1, 2022, having served since January 2020 as Chief Scientific Officer at Agios Pharmaceuticals, where the research focus was initially oncology and genetically defined diseases (GDD), later driving the portfolio to sole GDD approaches. Prior to Agios, Bruce spent 25 years at Bristol-Myers Squibb (BMS) and its legacy companies, working across all therapeutic areas and drug modalities. For more than two decades, he held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms, India R&D site, and different stages of discovery. In early 2017, he became the first head of the BMS Translational Medicine function, where he built a cohesive team of over 300 scientists and specialists covering biomarkers through data science and pharmaco-diagnostics. During his tenure with BMS, Dr. Car contributed to progressing approximately 250 internally discovered drug candidates and over 18 drug registrations. Dr. Car left BMS as the interim head of Drug Discovery. Dr. Car received a degree in Veterinary Medicine from The University of Melbourne, Victoria, Australia (’83), and his Ph.D (’89). from Cornell University, NY, USA. He holds specialty certifications in anatomic and clinical pathology. Dr. Car undertook his postdoctoral studies in immunology and inflammation at the Theodor Kocher Institute, University of Berne and ETH/University of Zurich in Switzerland.

*DVM equivalent Australian qualification (BVSc Hon).

Warren  Volles, General Counsel & Chief Legal Officer

Warren Volles

General Counsel & Chief Legal Officer

Tanya Fischer M.D., Ph.D., Chief Development Officer & Head of Translational Medicine

Tanya Fischer M.D., Ph.D.

Chief Development Officer & Head of Translational Medicine

X

Tanya Fischer M.D., Ph.D.

Tanya Fischer currently is the Chief Development Officer and Head of Translational Medicine at Biohaven. Prior to joining Biohaven in 2022, she served as the Vice President of CNS Development at Alnylam Pharmaceuticals and was a Global Project Head at Sanofi in the Multiple Sclerosis, Neurology and Gene Therapy Therapeutic Area. While at Alnylam, she was responsible for expanding the CNS pipeline, initiating a Phase 1 trial. At Sanofi, she was responsible for leading the flagship global project teams in clinical development (Phase 1 through Phase 3) for a rare genetic form of Parkinson’s Disease and related rare neurodegenerative diseases (such as Gaucher disease (type 3) and GM2 gangliosidosis, as well as genetic forms of ophthalmology.

As a physician-scientist, Dr. Fischer also works closely between research and clinical development for internal and external programs in both the Neurology and the Rare Disease therapeutic areas. Moreover, she continued to maintain a clinical practice up until January 2020, volunteering her time at the Veteran’s Hospital (VA) in an outpatient neurology clinic.

Dr. Fischer is a neurologist, with clinical subspecialties in demyelinating diseases and chronic neuropathic pain. Dr. Fischer did her Neurology residency at Yale New Haven Hospital. As an Associate Professor at Yale University in Neurology, her VA-supported academic research focused on genetic and acquired forms of pain (ion channels (especially in Nav 1.7) and diabetic neuropathy) with a variety of peer-reviewed paper. She also was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE) Award in 2011. The PECASE Awards are intended to recognize some of the finest scientists and engineers who, while early in their research careers, show exceptional potential for leadership at the frontiers of scientific knowledge during the twenty-first century.

Maryellen McQuade, Chief Talent & Sustainability Officer

Maryellen McQuade

Chief Talent & Sustainability Officer

X

Maryellen McQuade

Maryellen has worked in pharmaceuticals and consumer medicines almost her entire career, starting at Bristol-Myers Squibb and most recently at Novo Nordisk. She has a deep understanding of the business, having worked alongside both commercial and R&D leaders, and operationalizing talent processes across multiple markets. While at Novo Nordisk, Maryellen served as the leader for the HR function in the United States, while also driving culture change and employee engagement efforts globally. She is known for her creative thinking, ability to break down complex problems and calm leadership style.

Maryellen will provide strategic leadership to foster the professional growth of our talent base, health of our culture, and guard our lean organizational structure to remain efficient as we grow. She will be responsible for developing our future generations of leaders, ensure transparency and communication with our employees, and ensure our continued belief in empowering and developing our employees.

Maryellen received her Master’s degree from Georgetown and BA from Pomona College in Claremont, CA. She resides in Princeton, NJ with her husband David and their two teenage daughters.

Elyse Stock, M.D., Senior Scientific Advisor

Elyse Stock, M.D.

Senior Scientific Advisor

X

Elyse Stock, M.D.

Dr. Stock has 30 years of clinical and drug development experience. After practicing psychiatry for 11 years she joined the pharmaceutical industry. Within the industry, Dr. Stock has spent the last 19 years at Bristol-Myers Squibb developingnumerous experimental agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular. She has led numerous large and complex programs across all aspects of development including those leading to the marketing of products such as ABILIFY®, ORENCIA®, and EMPLICITI®. She is an experienced developer of both biologic and non-biologic compounds. Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children’s Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.

Michael Bozik, M.D., President, Ion Channel Research & Development

Michael Bozik, M.D.

President, Ion Channel Research & Development

X

Michael Bozik, M.D.

Dr. Bozik has more than 30 years of experience in drug discovery and development and in academic research and practice. He comes to Biohaven after 17 years as President and CEO of Knopp Biosciences, a Pittsburgh-based biotechnology company that discovered BHV-7000. Over his career, Dr. Bozik has led pioneering discovery and clinical research programs in cancer immunotherapy, neurodegeneration, neuroexcitablility, and neuropsychiatric diseases, including leading the team that secured the New Drug Approval of ABILIFY® (aripiprazole). He is the author of more than 20 peer-reviewed publications, the principal investigator on NIH grants totaling more than $3 million, and an inventor on 28 issued U.S. patents related to drugs developed for ALS, epilepsy, and asthma.

Dr. Bozik previously served at Bristol-Myers Squibb as Vice President of Neuroscience Clinical Development and Vice President of Research, Development, and Business Operations in the Specialty Pharmaceuticals and Consumer Medicines Group. He directed the Brain Tumor Center at the University of Pittsburgh Cancer Institute and headed its Division of Neuro-Oncology. He is a recipient of the Ernst & Young Entrepreneur of the Year Award and a director of Areteia Therapeutics and Life Sciences PA. He received his M.D. from the University of Pittsburgh and conducted his fellowship training in neurology and neuro-oncology at the University of Michigan and the University of Pittsburgh.

George Clark, CPA, Vice President, Chief Accounting Officer

George Clark, CPA

Vice President, Chief Accounting Officer

X

George Clark, CPA

George has over 10 years of experience in the areas of SEC reporting, accounting advisory, internal controls, and corporate finance. He joined Biohaven from KPMG, LLP where he was a Senior Manager in the Hartford Audit Practice, leading various audits for one of the firm’s largest clients. Prior to KPMG, George held positions in the finance group at The Hartford Financial Services Group, Inc. and began his career at PricewaterhouseCoopers, LLP in the Hartford Assurance and Advisory Practices. George is a graduate of the University of Connecticut where he earned Bachelor and Master of Science degrees in Accounting and is a Certified Public Accountant.

Jimi Ayodele, MBA, Senior Vice President, Finance

Jimi Ayodele, MBA

Senior Vice President, Finance

X

Jimi Ayodele, MBA

Jimi joins Biohaven with more than 28 years of finance experience. Most recently, with Otsuka America Pharmaceutical, Inc., Jimi served in numerous, evolving roles during his 16-year tenure. His experiences included establishing the first corporate planning function, transaction support leadership for business development, finance alliance and partnership management lead, and R&D finance. From his start with Otsuka, Jimi led finance activities for the commercialization and launch of Abilify, as well as other successful assets in the renal, oncology, and neuroscience categories. Jimi ended his tenure with Otsuka as head of operations and finance for the three-year-old Otsuka-incubated startup, Otsuka Digital Health. Prior to his time at Otsuka, Jimi’s experience included time with Celera Genomics during the race to map the human genome, as well as work with PricewaterhouseCoopers both domestically and in Europe. He earned his accounting degree from Morgan State University and MBA from New York University. Jimi is also a Certified Public Accountant.

Richard Bertz, Ph.D., Senior Vice President, Clinical Pharmacology & Pharmacometrics

Richard Bertz, Ph.D.

Senior Vice President, Clinical Pharmacology & Pharmacometrics

X

Richard Bertz, Ph.D.

Rick Bertz joined Biohaven Pharmaceuticals in 2019 as Vice President, Clinical Pharmacology and Pharmacometrics. Rick has worked in pharmaceutical industry for over 25 years, most recently as Vice President and Head, Clinical Pharmacology and Pharmacometrics at Bristol-Myers Squibb.

Rick has been involved in all phases of clinical drug development, with a focus on the analysis and interpretation of clinical pharmacology and pharmacometric data. He has mentored, coached, managed and developed numerous clinical pharmacologists and drug development scientists. Rick has been integrally involved in the completion of components of NDA submissions that have led to worldwide regulatory approval for several antiviral drugs for treatment of HIV and HCV.

Rick has coauthored over 75 peer-reviewed publications and given numerous invited presentations at national and international scientific meetings. He previously held a faculty appointment as Professor and Associate Dean at the University of Pittsburgh, School of Pharmacy, where he is currently an Adjunct Professor. Rick received a BS in Pharmacy from the University of Wisconsin and earned his PhD from the University of Pittsburgh Clinical Pharmaceutical Scientist Graduate Program.

Amy O'Donnell, J.D., M.D., Vice President, Head of Pharmacovigilance

Amy O'Donnell, J.D., M.D.

Vice President, Head of Pharmacovigilance

X

Amy O'Donnell, J.D., M.D.

Amy O’Donnell, J.D., M.D., is a neurologist who joined Biohaven as Vice President, Head of Pharmacovigilance after 18 years in the pharmaceutical industry. Amy spent the last 6 years at Janssen where she led the Safety Management Team for two Neuroscience drugs and served as medical lead for a medical affairs post-marketing study.

Prior to that, she spent 7 years at Inventiv Health, where she served as medical monitor for studies in a variety of Neuroscience indications including pain, multiple sclerosis, autism, Parkinson’s disease and schizophrenia. Amy spent the early part of her career at Bristol-Myers Squibb in drug safety and Neuroscience clinical development. Amy received her MD from Brown University Medical School. After finishing her Neurology residency at Brown, she completed a fellowship in Headache Disorders at Harvard. She also has a law degree from New York University Law School and a B.A. from Bryn Mawr College.

David Pirman, Vice President, Biology & Biochemistry

David Pirman

Vice President, Biology & Biochemistry

X

David Pirman

David has  over 10 years experience in drug discovery primarily focused on understanding fundamental metabolism applied to oncology, immunology and genetically defined diseases. Previously, he lead the metabolism and proteomics department at Agios Pharmaceuticals. He spent over eight years starting  as bench level scientist working and leading projects across the portfolio and indication space. The team he led supported all aspects of a project’s life cycle from developing a fundamental understanding of target biology to leading translational approaches to better understand clinical observations. He and his team’s efforts have led to over 20+ publications and numerous successful academic collaborations at Agios and contributed to the successful development of IDH inhibitors and PK activators. His main interests lie at the intersection of technology and biology particularly applied to drug discovery. He recently joined Biohaven to lead the development of our discovery labs in Cambridge, MA.

David earned is PhD at the University of Florida under Rick Yost and completed his postdoc at Pfizer in Groton, CT where he built metabolism platforms to better understand the impacts of pharmacological regulation of enzymes in metabolic disease indications.

Steven Dworetzky, Ph.D., Senior Vice President, Ion Channel Research & Development

Steven Dworetzky, Ph.D.

Senior Vice President, Ion Channel Research & Development

X

Steven Dworetzky, Ph.D.

Dr. Dworetzky’s career spans more than 30 years of drug discovery, primarily in ion channel pharmacology of the central nervous system. Before joining Biohaven, he was Chief Scientific Officer and Senior Vice President of Discovery Research at Knopp Biosciences, a Pittsburgh-based biotechnology company, where he led the discovery and preclinical development of BHV7000 and the creation of Biohaven’s Kv7 activator platform and led nonclinical dexpramipexole research in eosinophil biology.

Over his 17 years at Bristol-Myers Squibb, he led discovery programs in neuroprotection, schizophrenia, and pain, and discovered and first cloned multiple members of the KCNQ gene family. He is an inventor on 17 issued U.S. patents and the author of more than 40 peer-reviewed publications.

Dr. Dworetzky received his Ph.D. in cell biology from the University of Florida, performed post-doctoral research at the University of Massachusetts Medical Center, and served as an Adjunct Assistant Professor of Molecular Physiology at Yale University.

Jennifer Porcelli, Vice President, Investor Relations

Jennifer Porcelli

Vice President, Investor Relations

Rajesh Kumar, Ph.D., Senior Vice President, Global CMC & Supply Chain

Rajesh Kumar, Ph.D.

Senior Vice President, Global CMC & Supply Chain

X

Rajesh Kumar, Ph.D.

Rajesh Kumar Ph.D. joined Biohaven as Vice President of Chemistry, Manufacturing, and Controls (CMC) in 2018. He has more than 20 years of experience in developing immediate and controlled release pharmaceutical dosage forms, including drug-device combination products. He has extensive experience and clear understanding of the phase appropriate requirements for developing products from feasibility to commercialization. Prior to joining Biohaven, he served as a Senior Director of CMC at the Proprietary Products Division of Dr. Reddy’s Laboratories/Promius Pharma where he was responsible for CMC and device related development, overseeing external R&D and manufacturing partners for exploratory, clinical and commercial products. At Dr. Reddy’s he was responsible for the development and commercial manufacturing of Zembrace® (autoinjector). Dr. Kumar also spent 13+ years at Alkermes, Plc with increasing responsibilities and represented or led the CMC function in the development of multiple long acting complex injectable products including BYDUREON®, Aristada®, Risperdal® Consta® and Vivitrol®

Dr. Kumar obtained his Bachelor and Masters degree in Pharmacy from India and his Ph.D. in Pharmaceutical Sciences from Auburn University, AL.

Gene Dubowchik, Ph.D., Senior Vice President, Molecular Technologies

Gene Dubowchik, Ph.D.

Senior Vice President, Molecular Technologies

X

Gene Dubowchik, Ph.D.

Gene has 30 years of experience in medicinal chemistry, specifically in Neuroscience and Oncology. He joined Biohaven from Bristol-Myers Squibb where he led efforts in antibody-drug conjugates for cancer and contributed to diverse neuroscience programs in migraine (CGRP antagonists), depression (CRF antagonists, ion channel blockers), FK-506 binding proteins (FKBPs, immunophilins), Alzheimer’s Disease (GSK-3 inhibitors) and sleep (melatonin agonists and antagonists). He oversaw chemist teams leading to the discovery of two CGRP receptor antagonist clinical candidates, BHV-3000 (formerly BMS-927711) for oral delivery, and BHV-3500 (formerly BMS-742413) for intranasal delivery. He also developed the dipeptide-based linkage system used in the antibody drug conjugate (ADC) Adcetris®, approved by the FDA in 2011, and numerous other ADCs now in clinical trials and pre-clinical development. Gene received his Ph.D. in organic chemistry from Princeton University and did postdoctoral work at the University of British Columbia. He received his bachelor’s degree from Franklin and Marshall College, majoring in chemistry and history.

David Stock, Ph.D., Vice President, Biostatistics

David Stock, Ph.D.

Vice President, Biostatistics

X

David Stock, Ph.D.

Dr. Stock has more than 20 years of experience developing biostatistical solutions for the pharmaceutical industry. David came to Biohaven from Bristol-Myers Squibb (BMS), where he was the Therapeutic Area Lead for Genetically Defined Diseases. While at BMS, David also served as Statistical Lead for late stage HIV compounds, and Head of Nonclinical Biostatistics. In addition, he oversaw the response-adaptive clinical trial which established the efficacy of Rimegepant. David’s publication record includes articles on evaluating the value of backup compounds in drug development, large sample inference techniques for high throughput screening, and numerous clinical trials. He is currently Co-chair of the Council of Biopharmaceutical Statistics, former Chair of the Quantitative Sciences in the Pharmaceutical Industry (QSPI) Committee and was an elected member of the PhRMA Biostatistics and Data Management Technical Group (BDMTG). David first entered the pharmaceutical industry from Brookhaven National Laboratory (BNL) where he worked on projects for the Nuclear Regulatory Commission and the Department of Energy. David received his Ph.D. in Applied Mathematics, with a specialization in Statistics, at the State University of New York at Stony Brook.

Stephen Kaplita, Senior Director, Biostatistics

Stephen Kaplita

Senior Director, Biostatistics

X

Stephen Kaplita

Stephen is a biostatistician with over 30 years of experience in the pharmaceutical industry.

He comes to Biohaven from Bristol-Myers Squibb where he worked on projects in neuroscience, virology and oncology. His work has helped lead to global registrational approvals for drugs to treat pain, depression, schizophrenia, and bipolar mania.

Stephen has also led teams to successful registrational approvals in pediatric indications in virology and oncology.

Stephen earned his M.S. degree in Statistics at the University of Connecticut.

Victoria Wirtz, M.S., Senior Director, Biostatistics

Victoria Wirtz, M.S.

Senior Director, Biostatistics

X

Victoria Wirtz, M.S.

Victoria is a biostatistician with over 28 years of experience in the pharmaceutical industry. She was previously employed at Bristol-Myers Squibb where she was promoted from protocol statistician to the virology lead for the HIV and HBV portfolio where she oversaw all phases of clinical trials. Victoria has led her teams to successful global filings for both adult and pediatric indications while also helping to build a new function within the statistics department, Planning and Execution (P&E). Victoria managed a team of P&E leads overseeing oncology, cardiovascular and virology, working closely with the internal teams and vendors to ensure high quality analyses. As a member of cross-functional teams, she has been part of due diligence for in-licensing assets as well as selecting statistical programming vendors. Victoria earned her M.S. in Biostatistics at the University of Minnesota.

Ashwini  Ghatpande, M.S., Vice President, Global Regulatory Documentation

Ashwini Ghatpande, M.S.

Vice President, Global Regulatory Documentation

X

Ashwini Ghatpande, M.S.

Ashwini has over 14 years of pharmaceutical industry experience in writing and editing clinical and regulatory documents and 10 years of diverse scientific research experience from academic institutions and pharmaceutical industry.

Prior to joining Biohaven, Ashwini worked at Bristol-Myers Squibb as a group director , where she led a team of writers to develop and implement regulatory documentation and product labeling strategy across therapeutic areas to support and facilitate global submissions and approvals. Ashwini’s medical writing expertise spans a wide variety of regulatory documents that are part of both US and international dossiers. In her previous role, she was part of a cross functional leadership team that implemented change management initiatives to improve cycle time and quality of regulatory documentation for global submissions. She brings extensive experience in resource planning, management and staff development to establish strategic, scientific, and technical expertise in support and delivery of high-quality regulatory documents. Ashwini earned her Masters and M.Phil in Molecular and Developmental Biology from the University of Pune, India.

Marianne Frost, M.A., Senior Vice President, Regulatory Affairs

Marianne Frost, M.A.

Senior Vice President, Regulatory Affairs

X

Marianne Frost, M.A.

Ms. Frost has over 20 years of drug development experience with 18 years in various roles within Regulatory Affairs. She joined Biohaven after 11 years at Bristol-Myers Squibb, 5 years at CuraGen Corporation, and 5 years at Wyeth working in the therapeutic areas of neuroscience, virology, immunology, oncology and women’s health. Her experience spans all phases of drug development from preclinical research through Phases 3 and marketed products. Her numerous successful health authority interactions globally include approval of a new drug application for Daklinza and several Abilify sNDAs in the U.S. Ms. Frost has a B.A. in psychology from Northeastern University and a M.A. in behavioral neuroscience from the University of Connecticut.

Lisa Stocking, M.S.P.H., Senior Director, Regulatory Affairs & Operations

Lisa Stocking, M.S.P.H.

Senior Director, Regulatory Affairs & Operations

X

Lisa Stocking, M.S.P.H.

Lisa has over 33 years of pharmaceutical industry experience in global drug development comprised of 17 years in Regulatory Affairs and Operations and 16 years in nonclinical laboratory drug development. Lisa has extensive knowledge of regulatory requirements for dossier development and submission for the US, EU, Australia and Canada in several therapeutic areas including neurology, virology, and oncology.

Lisa joined Biohaven after spending 12 years in Global Dossier Management at Bristol-Myers Squibb. Lisa’s 16 years of nonclinical laboratory experience in metabolism and pharmacokinetics included positions at Bristol-Myers Squibb, Bayer and Marion Merrell Dow. Lisa’s work has supported many successful filings, approvals, and other regulatory commitments across the globe.

Lisa received her Master of Science in Public Health – Toxicology from the University of North Carolina, Chapel Hill and her Bachelor of Science – Toxicology from Northeastern University.”

Celia Coles, Senior Director, Scientific Writing & Regulatory Submission Sci Writing & Reg Submission

Celia Coles

Senior Director, Scientific Writing & Regulatory Submission Sci Writing & Reg Submission

X

Celia Coles

Celia comes to Biohaven with over 25 years of experience supporting regulatory submission strategy and documentation. Prior to Biohaven Celia spent 17 years at Bristol-Myers Squibb supporting NDAs for virology products including Reyataz, Evotaz, and Baraclude. Before BMS she spent four years at Purdue Pharma supporting an experimental injectable local anesthetic.

At Biohaven Celia is currently leading documentation strategy, storyboarding/messaging for planned NDAs, summary document planning and development, NDA filing timelines and contingency planning.

Celia received her MA in English and American Literature at the University of Illinois at Champaign Urbana, IL and her BA Hons in English literature at the University of Exeter, England.

Anthony Gentile, MBA, Senior Director, Clinical Operations & Program Finance

Anthony Gentile, MBA

Senior Director, Clinical Operations & Program Finance

X

Anthony Gentile, MBA

Mr. Gentile has over 27 years of pharmaceutical experience at Bristol-Myers Squibb in the areas of Drug Discovery, Clinical Operations and Finance. While working in Neuroscience Drug Discovery at Bristol-Myers Squibb, Mr. Gentile worked on the team that discovered a novel treatment for Non-24 Sleep-Wake Disorder. As a Protocol Manager in Clinical Operations, Mr. Gentile managed several pneumonia and sinusitis studies conducted for the development of the antibiotic Tequin. For the 15 years prior to joining Biohaven, Mr. Gentile worked as an Associate Director in Finance where he managed the development budgets and financial forecasts for several key BMS products including Abilify, Reyataz, Daklinza, Sunvepra, Nulojix, Orencia, Empliciti, Opdivo and Eliquis. Mr. Gentile also functioned as the Finance Alliance Manager between BMS and Pfizer for the clinical development of Eliquis. Mr. Gentile holds a B.S. in biology from Eastern Connecticut State University, a M.S. in biology from the University of Hartford and a M.B.A. in Finance from Rensselaer Polytechnic Institute. Prior to BMS, Mr. Gentile worked as an Extrusion Chemist at U.S. Surgical Corporation.

Javier Gonzalez, Vice President, CMC Technical Operations

Javier Gonzalez

Vice President, CMC Technical Operations

X

Javier Gonzalez

Biopharmaceutical executive with over 20 years of Domestic and International experience in the areas of Technical Operations, Supply chain, External Manufacturing, Product Launch, Drug-Device Combination Products, Packaging Development, Human Factors, Equipment Engineering & Process Development. Javier is a functional leader with significant experience in the development and launch of numerous pharmaceutical & biologics products in several dosage forms: intranasal, injectable, oral solids, and topical. Many products are well recognized global brands generating several billion dollars in revenues. Javier joined Biohaven from Dr. Reddy’s Laboratories where he was Director, Technical Operations. He also worked in various technical roles of increased responsibilities at Bristol-Myers Squibb, Johnson & Johnson, and Pfizer. Javier holds an MBA from University of Phoenix, a BSME from Polytechnic University of Puerto Rico and numerous courses, certificates and trainings from various Universities.

Ajaya Kumar Reka, Ph.D., Vice President, Drug Product Development

Ajaya Kumar Reka, Ph.D.

Vice President, Drug Product Development

X

Ajaya Kumar Reka, Ph.D.

Ajaya comes to Biohaven from Dr. Reddy’s Laboratories Inc (DRL) where he served as product development lead for five years. He led the product development for multiple projects, in neurology, dermatology, and oncology therapeutic areas, from ideation stage to Phase 2/3 clinical trials and commercialization. Before DRL, Ajaya served as a faculty in Internal Medicine Department of University of Michigan, Ann Arbor, USA. Ajaya published his research work in highly rated scientific journals, and he is one of the inventors on many patents. Before moving to the USA, he spent over ten years in the discovery and development of NCEs at Dr. Reddy’s Discovery Research Foundation, India.

David Leahy, Ph.D., Vice President, Drug Substance Development

David Leahy, Ph.D.

Vice President, Drug Substance Development

X

David Leahy, Ph.D.

Dr. Leahy has 17 years of pharmaceutical process chemistry experience, with expertise in drug substance manufacturing, catalysis and green chemistry.

Prior to joining Biohaven in 2020, he had roles of increasing scope from Takeda Pharmaceuticals and Bristol-Myers Squibb. At Takeda, he built capabilities in process chemistry automation, biocatalysis, and green micellar chemistry leading to one of the industry’s first manufacturing processes of a complex API almost exclusively in water instead of organic solvents. He also led multiple academic collaborations to solve complex chemistry challenges leading to advances in catalytic asymmetric nucleotide couplings, as well as nanocatalysis in aqueous micelles.

At Bristol-Myers Squibb, he led process chemistry efforts to develop the manufacturing route and process for the drug substance of Nurtec® ODT. Dr. Leahy also has extensive experience in green chemistry and sustainability, having served as a co-chair of the ACS Green Chemistry Institute Pharmaceutical Roundtable and program chair and advisory board member of the ACS Green Chemistry and Engineering Conference.

He completed his Ph.D. in organic chemistry from Indiana University.

Megan Dow, Ph.D., Vice President, Head of Portfolio & Corporate Strategy

Megan Dow, Ph.D.

Vice President, Head of Portfolio & Corporate Strategy

X

Megan Dow, Ph.D.

Throughout Megan’s career, she has focused on the nexus between science and business. As a sell-side analyst on Wall Street, Megan covered innovative biotech companies, most of whom were developing assets focused on immune regulation, and novel genetic and nucleic acid technologies.

She left banking however to take on a unique opportunity as Senior Life Science Advisor for Denmark based in NYC, where she led the U.S. investment, partnering, and engagement strategies for Danish biotech and pharma companies, and guided public engagement for key political and Royal figures pertaining to the healthcare agendas.

Megan joined Biohaven from Pfizer, where she worked in the Chief Business Office on R&D Strategy across the portfolio. An engaged member of the scientific business community, Megan is on the Steering Committee for the New York Academy of Sciences, and is a board member of the Danish American Chamber of Commerce, and she volunteers as a business and scientific strategy mentor for entrepreneurship groups. She holds her Ph.D. in Pathobiology and Immunology from New York University School of Medicine.

Jon Blaskovich, Director, Information Technology

Jon Blaskovich

Director, Information Technology

X

Jon Blaskovich

Jon has over 25 years of experience in Information Technology.

Prior to Biohaven, Mr. Blaskovich held the position of Vice President of Technology for Epsilon and has overseen the technical operations for one of the largest independent Marketing Services companies in North America, serving Fortune 500 clients.

Jon holds a B.S. from Rochester Institute of Technology.

David Saunders, Director, Finance

David Saunders

Director, Finance

Debora Robertson, Executive Director, Clinical Supply Operations

Debora Robertson

Executive Director, Clinical Supply Operations

X

Debora Robertson

Debbie has over 20 years of experience with clinical supplies management in all phases of development with a primary focus in neuroscience, virology and oncology.

Prior to joining Biohaven in 2019, Debbie had roles of increasing responsibility within the Clinical Supply Operations team at Bristol-Myers Squibb where she led the team of up to 15 people in Wallingford, CT. She subsequently worked at Sunovion in Massachusetts.

Debbie has extensive experience with many different oral/parental formulations and their associated packaging/labeling requirements for global use, including high precision labeling for syringes. She has experience with implementing and managing multiple RTSM/IRT and clinical forecasting systems for proactive management of clinical supplies and has a strong interest in improving processes through the use of Lean Sigma tools.

Debbie has a BS in Pharmacy from UConn and started her career as a clinical pharmacist at Johns Hopkins Hospital in Baltimore.

Beth Morris, Vice President, Clinical Operations

Beth Morris

Vice President, Clinical Operations

X

Beth Morris

Beth brings 25 years of experience in the Pharmaceutical, Biotech and CRO industries and has worked in all phases of clinical research from Phase 1 through Phase 4 in various roles such as Clinical Research Associate, Clinical Trial/Site Manager, Acquisition Integration Lead and Operations Lead within the CNS and Oncology therapeutic areas. Prior to joining Biohaven in 2016, Beth spent 14 years in the Clinical Operations department at Bristol-Myers Squibb where she was responsible for operational oversight of large-scale global programs with focus in migraine, pain indications, and psychiatry in addition to holding direct management responsibilities within the Regional Clinical Operations group. Beth also worked at several CROs, such as Scirex Corporation, and INC. Prior to her work in the Pharmaceutical Industry, Beth worked as a social worker at a private school for children. She earned her BA in Psychology from Central Connecticut State University.

Melissa Beiner, M.D., Director, Research & Development

Melissa Beiner, M.D.

Director, Research & Development

X

Melissa Beiner, M.D.

Dr. Beiner was formerly a board certified, practicing pediatrician prior to joining Biohaven in 2017. Dr. Beiner conducted pre-clinical research in neuroscience, focusing on spinal cord injury and neuronal regeneration both at the Yale School of Medicine Neurosurgical Research Laboratories and at The Miami Project to Cure Paralysis. In her current role at Biohaven, Dr. Beiner is the Director of Research and Development and is the program lead for the spinocerebellar ataxia (SCA) program. Dr. Beiner also leads a clinical study in trigeminal neuralgia and supports the OCD program.

A graduate of Yale University School of Medicine, Dr. Beiner completed her internship and residency in Pediatrics at the Yale New Haven Children’s Hospital.

Tracy Nepomuceno, Associate Director, Clinical Operations

Tracy Nepomuceno

Associate Director, Clinical Operations

X

Tracy Nepomuceno

Tracy joins Biohaven with over 20 years of experience in the pharmaceutical industry primarily in clinical operations. Tracy spent 17 years at Bristol-Myers Squib working in neuroscience, anti-infective, oncology and rare diseases clinical research. She subsequently worked at Pfizer in vaccine and rare diseases clinical operations prior to joining Biohaven in 2020.

Tracy has a BS in Pharmacy from the University of Connecticut and started her career as a pharmacist at Hartford Hospital.

Francine  Healy, Exec. Director, Scientific Writing & Regulatory Submissions

Francine Healy

Exec. Director, Scientific Writing & Regulatory Submissions

X

Francine Healy

Francine Healy has over 22 years of scientific research experience, including 13 years of neuroscience research in pharmaceutical drug development at Bristol-Myers Squibb and in academia at Yale School of Medicine. Prior to joining Biohaven, Francine spent the previous 8 years in the Global Scientific and Regulatory Documentation group at Bristol-Myers Squibb where she was responsible for development and implementation of regulatory document strategy. Her experience spans across multiple therapeutic areas including neuroscience, oncology, immunology, and immuno-oncology. Her work has supported numerous successful global filings, approvals, and other regulatory commitments across the US, EU, and Japan.

Gilbert L'italien, Ph.D., Senior Vice President, GHEOR & Epidemiology

Gilbert L'italien, Ph.D.

Senior Vice President, GHEOR & Epidemiology

X

Gilbert L'italien, Ph.D.

Gil is an accomplished Health Economics and Outcomes Research (HEOR) executive with over 25 years of global and regional HEOR/Epidemiology experience in both academia and industry across a wide variety of disease areas, with emphasis in the neuroscience field. Gil has held roles of increasing responsibility previously at Bristol Myers Squibb Company, and most recently at Alexion Inc and Biogen Inc. He has deep expertise with regard to orphan disease drug development, psychometric and functional scale validation and real-world evidence generation to support regulatory and reimbursement objectives. Prior to his industry roles, Gil served as Cardiovascular Research Director at Mass General Hospital and held a faculty appointment at Harvard University.

Gil is also a committed volunteer, devoting his time and resources to helping underserved children globally and our vulnerable elderly population in the U.S. Gil earned his PhD in Epidemiology/Biostatistics from the Boston University School of Public Health and has served as Adjunct Assistant Professor at Yale University School of Medicine.

Chris Jensen, Pharm. D., MBA, Senior Director, Medical Strategy

Chris Jensen, Pharm. D., MBA

Senior Director, Medical Strategy

X

Chris Jensen, Pharm. D., MBA

Dr. Jensen has over 5 years of pharmaceutical industry and medical affairs experience. Before joining Biohaven, Dr. Jensen was last employed at Alexion Pharmaceuticals and also previously completed internships at Bristol-Myers Squibb, and Sanofi Genzyme. His experiences range across a number of therapeutic and functional areas including medical affairs, clinical development, medical information, and business development. Dr. Jensen graduated from the University of Connecticut where he received his Doctor of Pharmacy and Master of Business Administration degrees.

Shuai Li, Ph.D., VP, Head of Business Developmen

Shuai Li, Ph.D.

VP, Head of Business Developmen

X

Shuai Li, Ph.D.

Shuai Li joined Biohaven in November 2017 as Manager in Business Development and Corporate Strategy. Shuai comes to us from IBM, where she worked as Managing Strategy Consultant and performed data analytics to address real time business challenges. Previously, she worked part-time at several healthcare investment advising groups including Beacon VP and conducted extensive market and scientific due diligence on early stage biotechs. Shuai has passed CFA Level III and holds a Ph.D. from Harvard University, where she focused on cutting-edge small molecule drug development at Harvard Medical School. Prior to that, Shuai received her dual BSc in Chemistry & Biology and Economics from Tsinghua University.

Matthew DeLawder, Director of Accounting

Matthew DeLawder

Director of Accounting

X

Matthew DeLawder

Matt brings over 20 years of Accounting and Finance experience to Biohaven including 16 years within the pharmaceutical industry at Bayer Healthcare and Alexion Pharmaceuticals where he was Senior Manager of Global R&D.

Dmitry Zuev, Senior IP Counsel

Dmitry Zuev

Senior IP Counsel

Debra Orlando, Senior Accountant

Debra Orlando

Senior Accountant

X

Debra Orlando

Prior to joining Biohaven in 2016, Deb was employed as a Staff Accountant, Real Estate Investments, at John Hancock in Boston, MA. She received a B.S. in Economics from Boston College, and an M.S. in Accounting from LIU Post.

Lia Donahue, M.A., Executive Director, Clinical Operations

Lia Donahue, M.A.

Executive Director, Clinical Operations

X

Lia Donahue, M.A.

Lia has over 18 years of combined clinical research experience at Yale University and the pharmaceutical industry including Bristol-Myers Squibb. Her passion and most of her focus in her career have been in neuroscience research, and she also has significant experience in oncology and virology research. For the past four years, Lia has been increasingly involved in the biotech industry and working to help start-up companies grow and thrive. She has her Masters in Psychology.

Susan Durham, Senior Director, Clinical Operations

Susan Durham

Senior Director, Clinical Operations

X

Susan Durham

Susan joined Biohaven with 30 years of clinical operations experience in the pharmaceutical industry, across all phases of clinical research and multiple therapeutic areas, having held various positions at Bristol-Myers Squibb, ranging from Clinical Site Monitor, Clinical Scientist, Protocol Manager, Associate Director-Global Clinical Operations and Strategy, Immuno-Oncology Submissions Operations Lead, to Relationship Lead-Strategic Clinical Trial Relationships.

She has successfully managed the operational oversight of large and complex global drug development programs, resulting in multiple marketing approvals for oncology and infectious diseases assets.

Prior to BMS, Susan held positions at the New York-Presbyterian Hospital/Weill-Cornell Medical’s Hypertension Center, Burroughs Wellcome Pharmacology Laboratories and the Bowles Center for Alcohol Studies at the University of North Carolina-Chapel Hill School of Medicine. Susan received a BA in Neuroscience and Behavior/Biopsychology from Vassar College, and has completed graduate coursework in Speech and Hearing Sciences at the University of North Carolina-Chapel Hill and in Public Administration at New York University.

Jennifer Hould, Associate Director, Clinical Operations

Jennifer Hould

Associate Director, Clinical Operations

X

Jennifer Hould

Ms. Hould has worked for more than 15 years in both industry and academia. Prior to joining Biohaven, Jennifer held increasing roles of responsibilities at Bristol-Myers Squibb, Pfizer Inc, Middlesex Hospital and Yale University. Within the pharmaceutical industry, Jennifer has experience working in multiple therapeutic areas including: neuroscience, virology and immuno-oncology. Jennifer has led multiple clinical trials and managed CROs in all clinical trial phases from Phase I to Phase IV and has worked at investigative sites within large and small pharmaceutical companies. Jennifer has an interest in data management with a focus on clinical data review. She earned her Bachelor of Arts degree at Coker College in South Carolina.

Laura Ruggiero, Associate Director, Clinical Operations

Laura Ruggiero

Associate Director, Clinical Operations

X

Laura Ruggiero

Laura brings more than 15 years of pharmaceutical industry experience to the Biohaven team. Prior to joining Biohaven, Laura worked for Bristol-Myers Squibb managing patient recruitment for clinical trials and then as a clinical site manager in the operations group. Her therapeutic areas of focus were neuroscience and oncology. Prior to joining BMS, she worked as a project manager for a medical education company.

Laura holds a bachelor’s degree in Business Administration from the University of New Haven.

Timothy McCormack, Senior Clinical Trial Lead

Timothy McCormack

Senior Clinical Trial Lead

X

Timothy McCormack

Tim has 17 years of clinical research experience in the areas of CNS and Oncology.

He came to Biohaven from Bristol-Myers Squibb, where he worked in both clinical operations and outsourcing management.

Tim earned his Bachelor of Arts at Keene State College.

Christine Lesczczynski, Clinical Trial Lead

Christine Lesczczynski

Clinical Trial Lead

X

Christine Lesczczynski

Christine brings more than 25 years of academia and pharmaceutical industry experience to the Biohaven team. Prior to joining Biohaven, she worked at the New York College of Podiatric Medicine as a clinical research coordinator and then at Bristol-Myers Squib as a senior clinical trial associate and site manager. At Bristol-Myers Squibb, she focused on neuroscience and oncology. Christine was instrumental in supporting several FDA filings and approvals.

Germana Pereira, Clinical Trial Lead, Clinical Operations

Germana Pereira

Clinical Trial Lead, Clinical Operations

X

Germana Pereira

Gerri brings more than 25 years of pharmaceutical industry experience to the Biohaven team. Prior to joining Biohaven, she worked at Bristol-Myers Squibb where she held several years of Clinical Trial Associate role in the Clinical Operations before moving into the Regulatory Department. At Bristol-Myers Squibb, she focused on therapeutic areas involving neurology and oncology. Gerri was instrumental in supporting several FDA filings. She supported and organized neurology and oncology studies in support of several approved FDA filings.

Jeri-Anne Finley, Senior Clinical Trial Lead

Jeri-Anne Finley

Senior Clinical Trial Lead

X

Jeri-Anne Finley

Jeri-Anne brings more than 30 years of pharmaceutical industry experience to the Biohaven team. Prior to joining Biohaven, she worked at Bristol-Myers Squibb where she held several administrative roles in clinical research before moving into site management. At Bristol-Myers Squibb, she focused on multiple therapeutic areas involving infectious disease, anti-virals (HBV, HCV), neurology and oncology. Jeri-Anne was instrumental in supporting several FDA filings. She supported and organized the non-clinical programs for in-vivo and in-vitro studies in support of the anti-infective FDA filings. She holds a bachelor’s degree from the University of Connecticut.

Micaela Forshaw, M.P.H., Senior Clinical Trial Lead

Micaela Forshaw, M.P.H.

Senior Clinical Trial Lead

X

Micaela Forshaw, M.P.H.

Micaela has been working in the pharmaceutical industry for seven years. She comes to Biohaven from Bristol-Myers Squibb where she worked in the Clinical Operations group and held multiple roles of increasing responsibility, including Senior Clinical Trial Associate and Clinical Site Manager. She has experience in multiple therapeutic areas including Oncology, Neurosciences and Immunology. Micaela earned her undergraduate degree at Southern Connecticut State University (Bachelor of Sciences in Public Health) and graduate degree at University of Connecticut (Masters of Public Health).

Juan Anchondo, Jr., Clinical Trial Lead, Clinical Operations

Juan Anchondo, Jr.

Clinical Trial Lead, Clinical Operations

X

Juan Anchondo, Jr.

Juan has been working in the clinical research industry for nine years with a primary focus in central nervous system diseases. Prior to coming to Biohaven, he worked at CRO, INC Research (now Syneos Health) and prior to that in the Phase 1 clinic from PPD in Austin, TX. Juan holds a Bachelor degree from Texas State University.

Deborah Price, M.L.S., Clinical Trial Lead

Deborah Price, M.L.S.

Clinical Trial Lead

X

Deborah Price, M.L.S.

Deborah has been working in the research field for 15 years. Prior to working at Biohaven, she worked in academic research that focused primarily on neurobehavioral research. Deborah has worked in multiples roles within Biohaven since the company inception. Deborah has a Bachelor of Arts degree in English from Trinity College, a Master of Arts in Teaching from Sacred Heart University and a Master of Library Science degree from Southern Connecticut State University.

Valerie Milewski, Senior Clinical Trial Associate

Valerie Milewski

Senior Clinical Trial Associate

X

Valerie Milewski

Valerie is an accomplished and highly organized Clinical Trial Associate with more than 20 years of experience in the pharmaceutical industry.

Prior to joining Biohaven, Valerie worked at Bristol-Myers Squibb for 18 years where she was an Executive Assistant in Infectious Diseases and Virology working on their HIV and Hep-C programs.

She has an Associate’s Degree in Science from Middlesex Community-Technical College.

Kathryn Phillips, Associate Clinical Trial Lead, Clinical Operations

Kathryn Phillips

Associate Clinical Trial Lead, Clinical Operations

X

Kathryn Phillips

Kathryn has research experience in college and graduated Lehigh University with a B.S. in Biology and a minor in Health, Medicine and Society.

Wendy Goss, Clinical Trial Associate

Wendy Goss

Clinical Trial Associate

Lucy Sullivan, Corporate Operations Manager

Lucy Sullivan

Corporate Operations Manager

X

Lucy Sullivan

Lucy has been working in the pharmaceutical industry for more than 15 years. Prior to joining Biohaven, she worked at Alexion Pharmaceuticals where she supported the Senior Vice President, US Commercial and Vice Presidents of the Neurology and Metabolics Business Units including support of the field sales and marketing teams. During her 11 years at Alexion, Lucy supported four drug launches for ultra-rare diseases. She excelled as an executive administrative coordinator and has a great deal of experience in travel and calendar management, budget management, vendor management, new hire on-boarding, congress and exhibit planning, coordinating hiring events, launch team management, planning off-site meetings, patient meetings and National Sales Meetings. Prior to working at Alexion, Lucy worked at Microsoft in various roles for seven years. Lucy graduated from the University of Connecticut with a B.A. in Communications.

Lorraine Soto, Accounts Payable Manager

Lorraine Soto

Accounts Payable Manager

Nanci Ellen Brake, Employee Relations

Nanci Ellen Brake

Employee Relations

Rachid Bakraoui, Property Manager

Rachid Bakraoui

Property Manager

Tracey Douglass, Director, Clinical Quality Compliance

Tracey Douglass

Director, Clinical Quality Compliance

X

Tracey Douglass

Tracey has over 20 years of Quality experience in the pharmaceutical industry with roles in Auditing, Compliance and Inspection Management at BMS, Alexion, Vion Pharmaceuticals and most recently Boehringer-Ingelheim. She has experience in multiple therapeutic areas including Oncology, Rare Disease, Virology and Neurosciences

Tracey received a B.S. in Business Administration and B.S. in Marketing followed with a Master’s in Business Administration from the University of New Haven.

Mary Donohue, M.S., PMP, Senior Director, Clinical Development

Mary Donohue, M.S., PMP

Senior Director, Clinical Development

X

Mary Donohue, M.S., PMP

Mary joined Biohaven with 19 years of experience in the biotech industry, with an emphasis in early phase clinical development program planning and management. She has worked in antiviral, pulmonary, nephrology, and neurology indications. She has coordinated successful multi-disciplinary project teams for the transition of novel compounds from discovery phase into Phase 3, including the development of PET imaging agents and various imaging modalities for use in diagnosis of Alzheimer’s disease and other neurological conditions. Prior to her work in biotech, Mary worked for 11 years in toxicology and occupational health & safety consulting in the chemical, industrial metals, and petroleum industries. Mary completed her B.A. in Biology from the College of the Holy Cross. She holds an M.S. in Environmental Health and Toxicology from the University of Massachusetts and has her certification as a Project Management Professional.

Samantha Hudspeth, Paralegal

Samantha Hudspeth

Paralegal

X

Samantha Hudspeth

Samantha comes to Biohaven with over 15 years in the pharmaceutical industry. Prior to Biohaven, she worked at Alexion Pharmaceuticals for 12 years, as a Project Manager in Global Training & Development. In this role she established a credentialing process to support the field staff’s access to customers, launched a global mentorship program, and managed all commercial National Sales Meetings, responsible for all logistics, planning, and execution. Additionally, she was responsible for configuring and launching a global, company-wide learning management system.

At Biohaven, Samantha works as a paralegal, with primary focus on our patent and trademark portfolio.

Samantha received her B.A. in Psychology at the University of Connecticut and more recently her Paralegal Certification from Duke University.

Kari Soderstrom, Lead Systems Integrator, Talent

Kari Soderstrom

Lead Systems Integrator, Talent

X

Kari Soderstrom

Kari has over ten years of experience in human resources and systems integration. She comes to Biohaven from Arvinas where she helped the company grow HR and IT resources in line with the rapidly expanding employee population. Kari loves the startup atmosphere of collaboration and has balanced positions across all departments including finance, information technology, and human resources. As Arvinas expanded from 15 employees to 100+, Kari specialized in combining information technology with human resources.

At Biohaven, Kari works to provide employees with the software platforms needed to create a community in a blossoming remote work culture. She received her Bachelor of Arts in English and Women’s Studies from Hope College in Holland, MI.

Katheryn Grossman, Director, Clinical Development

Katheryn Grossman

Director, Clinical Development

X

Katheryn Grossman

Kathy, is a certified Physician Assistant (PA-C) with clinical patient care experience in many areas of medicine including orthopedics, surgical, emergency, urgent care, and primary care. Kathy has history in the pharmaceutical industry working for Pfizer Pharmaceutical as a Research and Development Process Organic Chemist prior to becoming a PA-C. She joined Biohaven in 2019 as Director of Clinical Development, where she utilizes her previous pharmaceutical and medical knowledge and experiences to helping manage clinical research trials in rare neurological diseases.

Kathy earned Master of Science in Physician-Assistant Studies at A.T. Still University in Mesa, Arizona and Bachelor of Science in Chemistry, Cum Laude, at San Diego State University in San Diego, California.

John Cahill, Associate Director, Information Technology

John Cahill

Associate Director, Information Technology

X

John Cahill

John has over 30 years of experience in various roles within IT. Much of his career was spent in the advertising/premedia space focused on infrastructure and corporate solutions.

Prior to joining Biohaven, John was directly responsible for the corporate technology, infrastructure, and policies for approx. 9000 production associates at Publicis. Before that, he worked for Vertis, Inc., where he transitioned to Vertis’ National Operations team from a Co-Director of Technology position after the acquisition of Gamma One. His group was responsible for all production and datacenter infrastructure across 30 U.S. locations.

Chris Barrett, Senior Vice President, Commercial Strategy, Common Disease

Chris Barrett

Senior Vice President, Commercial Strategy, Common Disease

X

Chris Barrett

Mr. Barrett possesses over 25 years of diverse commercial experience in the biotech/pharmaceutical industry and has held several senior leadership positions in Managed Markets, Marketing, and Sales. He joined Biohaven in 2019 in the role of Senior Vice President, Managed Markets & Government Affairs and served as a key member of the commercial management team for the launch of Nurtec.

In previous roles with Boehringer-Ingelheim, Schering-Plough, Johnson & Johnson, Caremark International, and DBV Technologies, Mr. Barrett gained extensive therapeutic area experience in neurology, cardio-metabolic, respiratory, oncology, and immunology. He has also held leadership roles for more than 10 product launches, including Managed Markets lead for Spiriva, and Marketing lead for Jardiance and Pradaxa; all three of which achieved blockbuster status. Mr. Barrett is a graduate of Manhattan College, where he earned a Bachelor of Science degree in Business Administration.

John Tilton, Chief Commercial Officer, Rare Disease

John Tilton

Chief Commercial Officer, Rare Disease

Anne Neumann, RN, BSN, Rare Disease Marketing Lead

Anne Neumann, RN, BSN

Rare Disease Marketing Lead

X

Anne Neumann, RN, BSN

Anne brings over 25 years’ experience in the healthcare, from nonprofit to clinical practice to various roles with the pharmaceutical industry. Anne received her Bachelor of Science in Nursing from Chamberlain University. She did her clinical practice at Western Connecticut Health where she practiced in several different specialties, including medical/surgical, oncology and neurology. Since then, Anne has worked as a nurse case manager for Alexion Pharmaceuticals, field nurse educator for Novartis Oncology, and oncology sales representative for Novartis, supporting several disease states. Anne became a product trainer for oncology at Novartis before joining Biohaven. Anne also continues to support her love of public health as chairmen of the board for the Housatonic Valley Health Department which she has supported for nine years, in several volunteer capacities, including growing the department during the Covid pandemic.

Lisa Kamen, MHA, Senior Director, Clinical Operations

Lisa Kamen, MHA

Senior Director, Clinical Operations

X

Lisa Kamen, MHA

Lisa joins Biohaven with 20+ years of experience within clinical operations, primarily in CNS and most recently also in Oncology. Lisa has held the role of Director of Clinical Operations at two different biotech companies and spent 14 years at Bristol-Myers Squibb where she was managed and oversaw pivotal clinical studies. Lisa led the Abilify Autism to a successful approval for treating irritability associated with autistic disorder in children and adolescents. Lisa holds a bachelor of science degree, with a biology / zoology focus from the University of Rhode Island and Master of Healthcare Administration from Quinnipiac University.

Meghan Lovegren, Director, Clinical Operations

Meghan Lovegren

Director, Clinical Operations

X

Meghan Lovegren

Meghan Lovegren is approaching 20 years of experience in clinical research. Prior to joining Biohaven, Meghan managed clinical studies in genetic diseases (Duchenne Muscular Dystrophy) and virology (HBV and HCV) at Bristol-Myers Squibb for 12 years. At BMS, Meghan ran global pivotal studies in both pediatric and adult populations. Prior to BMS, Meghan worked at Pfizer, Yale University and Memorial Sloan-Kettering Cancer Center. She has a BS in Biology from the University of Minnesota, College of Biological Sciences.

Caroline Dircks Ph.D., Vice President, Corporate Operations

Caroline Dircks Ph.D.

Vice President, Corporate Operations

X

Caroline Dircks Ph.D.

Caroline has worked in the pharmaceutical industry for over 25 years primarily in R&D operations.

Caroline spent 14 years at Bristol Myers Squibb in R&D operations, her most recent role as Head Regional R&D operations and Schedule management. Her overall responsibilities included the oversight of the Specialty (non-oncology) portfolio including CV, IMS, Virology, Fibrotic Disease and Genetically Defined Diseases as well as managing licensing, partnering and acquisition opportunities. In addition, Caroline had oversight of R&D operations in China and Japan.

Prior to joining BMS, Caroline spent eight years at Vion Pharmaceuticals, starting as a bench scientist in Microbiology and ending her tenure as the Director of Quality Control/ Analytical and Bio-Analytical Development and Manufacturing where she was responsible for all pre-clinical and clinical analytical development for biologics and small molecules as well as analysis of clinical samples and all operational logistics to support clinical PK/PD.

Caroline received her BA in Biochemistry from Clark University and her PhD in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and completed her post-doctoral work at Yale University.

Lindsey  Lair, M.D., MBA, F.A.A.N., Vice President, Clinical Development

Lindsey Lair, M.D., MBA, F.A.A.N.

Vice President, Clinical Development

Azim Munivar, M.D., Medical Director, Research & Development

Azim Munivar, M.D.

Medical Director, Research & Development

Lopa Bakrania, Executive Director, CMC - RA

Lopa Bakrania

Executive Director, CMC - RA

X

Lopa Bakrania

Dr. Lopa Bakrania has 16 years of pharmaceutical process chemistry and CMC regulatory affairs experience. She is the head of CMC regulatory affairs at Biohaven.

Prior to joining Biohaven in 2021, she spent 9 years as a CMC regulatory technical documentation strategist at Bristol Myers Squibb. She has led multiple early and late-stage global CMC submissions, one of them being Sotyktu (deucravacitinib), which she managed from early development to the marketing application. Dr. Bakrania spent early part of her career as a process chemist at Bristol Myers Squibb. During which time she was contributed toward the development of the manufacturing route and process for the drug substance of Nurtec® ODT. Dr. Bakrania completed her Ph.D. in organic chemistry from University of Michigan-Ann Arbor.

Laura Heller, Executive Director Medical Strategy

Laura Heller

Executive Director Medical Strategy

Neal Sharpe, Executive Director, of Nonclinical Optimization and Development

Neal Sharpe

Executive Director, of Nonclinical Optimization and Development

X

Neal Sharpe

Neal has worked in Toxicology and Preclinical Development for over 30 years.  Neal’s work experience has crossed multiple therapeutic areas including neuroscience, infectious disease, oncology and rare disease in various modalities; small molecule, biologics, oligonucleotides and cell therapies.

Prior experience includes roles at Schering-Plough, Merck, Biogen and small biotech companies supporting toxicology, DMPK, and translational sciences across discovery and preclinical development through registration.  Neal received a PhD in neuroscience from Rutgers, The State University of NJ. He is originally from New Jersey and currently lives in Upstate New York.

Heather Sevinsky, Executive Director, Clinical Pharmacology & Pharmacometrics

Heather Sevinsky

Executive Director, Clinical Pharmacology & Pharmacometrics

X

Heather Sevinsky

Heather has worked in clinical pharmacology drug development for 15 years across all phases of drug development, most recently at Arbutus Biopharma, where she was senior director, clinical pharmacology and compound development lead for their RNAi targeting chronic hepatitis B infection. Prior to Arbutus, her focus was clinical pharmacology and pharmacometrics in HIV drug development at Bristol Myers Squibb and ViiV Healthcare.

Heather received Bachelor and Master of Science Degrees from the University of North Carolina at Wilmington and has extensive training in the area of Clinical Pharmacology.

Volkan  Granit, M.D., MSc, Medical Director, Clinical Development

Volkan Granit, M.D., MSc

Medical Director, Clinical Development

X

Volkan Granit, M.D., MSc

Volkan Granit, M.D., MSc, joins Biohaven as Medical Director, Clinical Development. He is a neurologist with expertise in neuromuscular medicine and brings 10 years of research and clinical experience in academia. He has served as an investigator in clinical trials targeting indications such as ALS, myasthenia gravis, and Guillain-Barré Syndrome, including those using novel modalities (antisense oligonucleotides and CAR-T cells). Before joining Biohaven, Volkan held faculty positions at Montefiore Medical Center/Albert Einstein College of Medicine followed by the University of Miami. At Montefiore, he established a Myasthenia Gravis Clinic and served as its Director and was co-Director of the Muscular Dystrophy Association Clinic. At University of Miami, he served as Medical Director of the multidisciplinary ALS Center and associate program director for the neuromuscular fellowship program. Volkan obtained his medical degree from Istanbul University (Turkey). He completed a Master of Neuroscience at Albert Einstein College of Medicine, and a neurology residency and neuromuscular fellowship at Montefiore Medical Center.

Peter Ackerman, Medical Executive Director, Clinical Development

Peter Ackerman

Medical Executive Director, Clinical Development

X

Peter Ackerman

Pete has spent his entire industry career in clinical development, having served as the medical monitor, clinical lead, and most recently, as a development team lead while working on assets across all stages of development lifecycle (Stage 1 through Stage 3/4). During his time in industry, he has played an important role in the successful clinical development, filing, and launch of multiple medications for both pediatric and adult indications. Pete’s work has been widely published in peer-reviewed journals and has been presented at numerous international conferences. Within clinical development, Pete has a special interest in data visualization and innovative and adaptive clinical trial design.

Pete completed a combined residency in internal medicine and pediatrics and a fellowship in adult infectious disease.

Jason Lerner, Medical Director, Research & Development

Jason Lerner

Medical Director, Research & Development

Connor Colbum, CPA, Benefits & SEC Reporting

Connor Colbum, CPA

Benefits & SEC Reporting

X

Connor Colbum, CPA

Connor has over seven years of experience in the areas of SEC reporting, internal controls, corporate finance, and employee benefits. He joined Biohaven from Xerox Holdings Corporation where he was a Manager of Accounting Policy, focused on financial reporting and accounting for employee benefits.

Prior to Xerox, Connor began his career at PricewaterhouseCoopers, LLP in the Hartford Assurance Practice. Connor is a graduate of the University of Connecticut where he earned Bachelor and Master of Science degrees in Accounting and is a Certified Public Accountant.

Suman Pathi, Ph.D., Research Investigator, Chemistry

Suman Pathi, Ph.D.

Research Investigator, Chemistry

X

Suman Pathi, Ph.D.

Suman joins Biohaven as Research Investigator, Medicinal Chemistry. He is currently working on designing and synthesizing small molecule Kv7.2/7.3 activators for treatment for epilepsy and neuropathic pain. Suman has over 8 years of medicinal chemistry experience both in the industry and academia and has worked on a range of various targets in developing lead candidates for CNS, cancer, and bacterial infectious diseases.

Prior to joining Biohaven, Suman was with Knopp Bioscience, where he was working on Kv7 channel targeting platform in optimizing lead small molecule potassium channel activators. He worked as Staff scientist at St John’s University, where he involved in identifying small molecule dual inhibitors of PARP and HDAC proteins targeting BRCA1 mutant breast cancers.

He did his post-doctoral at Rowan University, where he led multiple projects in the hit-to-lead phase which focused on design, synthesis, and optimization of small molecules for treatment of TNBC diseases and bacterial infections. Suman holds a Ph.D. degree in Organic Chemistry from Indian Institute of Chemical Technology. He is an innovator with few patents to his credit.

Vanessa Byles, Senior Research Investigator

Vanessa Byles

Senior Research Investigator

Wes Kazmierski, Senior Director, Chemistry

Wes Kazmierski

Senior Director, Chemistry

X

Wes Kazmierski

Wes has 30 years of experience in synthetic and medicinal chemistry, primarily in Virology, Cancer and Neuroscience therapeutic areas. He is currently involved in developing new medicinal chemistry approaches to protein degradation, novel syntheses of homogeneous, well-structurally defined ADCs and in small molecule drug discovery, further expanding Biohaven’s MoDE™, MATE™ and ARM™ platform technologies. Wes joined Biohaven’s legacy company Kleo Pharmaceuticals in 2020, where he led discovery effort of Covid MATE™ BHV-1200. Prior to joining Biohaven, Wes led multiple discovery teams at ViiV Healthcare and GlaxoSmithKline, delivering many small molecule clinical compounds (HCV protease inhibitor, HCV NS5A inhibitor, HIV CCR5 inhibitor) and a marketed HIV-protease inhibitor – Fosampernavir®. Wes obtained his Ph.D. degree in organic chemistry from the University of Arizona, where he helped to develop the one-bead-one-peptide (OBOC) combinatorial chemistry library approach, and M.Sc. in organic chemistry from Warsaw University. Prior to joining the pharmaceutical industry, Wes was appointed as an Assistant Professor at the University of Rhode Island. He was a recipient of a Gold Medal at the International Chemistry Olympiad.

Gregory Hebrank, Advisor, Clinical & Discovery

Gregory Hebrank

Advisor, Clinical & Discovery

X

Gregory Hebrank

Prior to joining Biohaven, Greg Hebrank was a co-founder, Board Member and EVP of Finance and Corporate Operations for 18 years at Knopp Biosciences (KBS) where he had responsibility for finance, audit, fundraising, corporate operations and participated in clinical development activities. Prior to KBS, he was an experienced public and private biotech equities investor and the co-founder of and partner in a successful clinical obstetrics and gynecologic practice in Pennsylvania.

He earned a B.S. in Biomedical Engineering from Vanderbilt University, an M.D. from Tulane University School of Medicine, and an MBA at Carnegie Mellon University’s Tepper School of Business. He completed his residency training in Obstetrics and Gynecology at Magee-Women’s Hospital of the University of Pittsburgh Medical Center and is an inventor on six issued U.S. patents.

He remains committed to the discovery and development of new medicines for indications of high unmet need and has a particular interest in ion channel discovery and development for the modulation of important smooth muscle indications.

Katy McGrath, Senior Research Scientist

Katy McGrath

Senior Research Scientist

X

Katy McGrath

Katy has been working in the lab animal science field for over 17 years. Prior to joining Biohaven she worked with Bristol Myers Squibb, Children’s Hospital of Philadelphia, Jackson Laboratory, Kleo Pharmaceuticals, and Regeneron. The part of her work she is most proud of is performing the in vivo work that went forward to support the IND of BVH-1100.

She graduated with a bachelor’s degree in Animal Science from the University of Connecticut.

Rachel Kopper, Senior Director, Corporate Operations

Rachel Kopper

Senior Director, Corporate Operations

X

Rachel Kopper

Rachel joins Biohaven with over 15 years of experience in the life sciences sector, responsible for essential aspects of corporate operations including finance, insurance, HR, IT, and investor relations. She has a solid reputation for anticipating organizational needs and uncovering unique solutions. Ms. Kopper also currently serves as National President-Emeritus of Women In Bio, an organization of more than 2,500 professional members committed to promoting careers, leadership, and entrepreneurship for women in the life sciences.

Previously she was instrumental in establishing the Pittsburgh chapter of WIB and remains an active volunteer. Earlier in her career she served as project manager focused on employee development for Boston-based The Forum Corporation and served as a forestry extension volunteer for the United States Peace Corps in Thailand. She holds an MBA from Chatham University and is a graduate of Westminster College, a western Pennsylvania liberal arts institution.

Lawrence Marcin, Senior Director, Chemistry & Site Lead

Lawrence Marcin

Senior Director, Chemistry & Site Lead

Meaghan Valliere, Senior Research Investigator

Meaghan Valliere

Senior Research Investigator

Shouqi Luo, Senior Director Nonclinical Optimization and Development

Shouqi Luo

Senior Director Nonclinical Optimization and Development

X

Shouqi Luo

Shouqi is a Board-certified toxicologist with more than 20 years of nonclinical safety assessment experience gained from CRO, biotech and pharmaceutical companies.

Shouqi’s prior focus was oncology, antiviral infections and women’s health in small molecules and biologics. He contributed to the approvals of dostarlimab, niraparib, telbivudine, plerixafor, and prasterone and is knowledgeable in all facets of life cycle management of drugs. He previously served as Executive Director at Atea Pharmaceuticals. Prior to that, he worked as Scientific Director of Toxicology at GSK and TESARO.

Shouqi studied Medicine in China and earned his Ph.D. in Physiology-Endocrinology from Laval University, Quebec, Canada.

Nova Yates, Director, SOX Compliance & Internal Controls

Nova Yates

Director, SOX Compliance & Internal Controls

Jane Marushak, Project Coordinator

Jane Marushak

Project Coordinator

X

Jane Marushak

Jane brings to Biohaven over 20 years of experience within the Medical Device industry.  Prior to joining Biohaven, she worked at Conmed Corporation, who acquired SurgiQuest, Inc., a capital venture backed Company. At SurgiQuest, Jane was a founding member, a leadership team member and held the role of HR and Business Operations Manager.  Her experience varied throughout the organization with experience in Managing Operations, Human Resources, Facilities, Quality and Regulatory support, Logistics as well as Coordination capacities.

Jane holds her AS Degree and is completing her BS Degree in Operations Management.

Kristina Mendela, IT Associate

Kristina Mendela

IT Associate

Michelle Coomes, Accounts Payable Specialist

Michelle Coomes

Accounts Payable Specialist

Alexander Bayden,  Principal Investigator

Alexander Bayden

Principal Investigator

X

Alexander Bayden

Alexander is a medicinal computational chemist. He has fifteen years of computer-aided drug design experience. He has a broad range of expertise in this field, having modeled small molecules, peptides and proteins during his career.

Alexander came to Biohaven as part of Kleo Pharmaceuticals acquisition. Previously in his career Alexander Bayden worked mostly on oncology programs, but also on some neuroscience and antiinfective programs at various startups: Kleo Pharmaceuticals, NLS Life Science and Therapeutics Discovery, IDEAYA Biosciences and CMDBioscience as well as a large pharmaceutical company AstraZeneca and Virginia Commonwealth University.

Alexander holds a Ph.D. in Chemistry from the University of Pittsburgh and a B.S. in Chemistry from Virginia Polytechnic Institute & State University.

Simone Nicholson, Ph.D., DABT, Director Nonclinical Optimization and Development

Simone Nicholson, Ph.D., DABT

Director Nonclinical Optimization and Development

X

Simone Nicholson, Ph.D., DABT

Simone’s 12 plus years of safety assessment and drug development experience spans multiple modalities including small molecules, biologics, and both viral vector and LNP delivery systems for gene therapy. Prior to joining Biohaven, Simone spent 10 years at MedImmune/AstraZeneca where she defined the safety assessment strategy and designed the preclinical investigative and regulatory tox studies for multiple biologics.

She has also conducted pharmacology studies to assess efficacy and developed in-house assays for small molecule safety assessment during her time at Dyax Corp and Epix Pharmaceuticals, respectively.

Simone has her Ph.D. in Immunology from Northwestern University and is board certified in Toxicology.

Ann Marie Rossi, Principal Scientist

Ann Marie Rossi

Principal Scientist

X

Ann Marie Rossi

Ann Marie comes to Biohaven with over 37 years of experience as a cell biologist, primarily focused on cancer. She started her career at Pfizer in their cancer group where she worked for 15 years. She then worked at CGI which was purchased by Gilead Sciences where she was able to train in immunological assays expanding my tool kit to include Basophil degranulation assays and dabble in platelet work.

From there, she went on to Arvinas where she was the first bench biologist and set up the screening cascade that identified their lead molecules currently in the clinic. This experience in protein degradation helped her integrate into Kleo where she was the cell biology assay designer that drove the CD38 program that produced Biohaven’s Phase 1 clinical program.

Ann Marie received her MS from the University of Kentucky.

Alex Greif, Director, Lab Operations & Facilities

Alex Greif

Director, Lab Operations & Facilities

X

Alex Greif

Alex has over 12 years of experience in operations, procurement & supply chain management gained in the biotech and robotics industries in Pittsburgh, PA. He  joins Biohaven as the Director, Lab Operations & Facilities where he oversees the day-to-day operations across all Biohaven Labs sites.

Prior to Biohaven, Alex spent a number of years working at Knopp Biosciences. His time at Knopp was followed by six years with Uber where he supported a team of engineers working on self-driving technology as a Supply Chain and Procurement Manager. Just before joining Biohaven, he worked as the Supply Chain Lead at a robotic vertical farming startup called Fifth Season.

Alex is a native of Pittsburgh and an alum of Robert Morris University where he received his BSBA.

Isis Amaye, Ph.D., Research Investigator, Chemistry

Isis Amaye, Ph.D.

Research Investigator, Chemistry

X

Isis Amaye, Ph.D.

Isis joins Biohaven as a Research Investigator with the Medicinal Chemistry team at Pittsburgh where she is currently working on designing and synthesizing small molecule Kv7.2/7.3 activators for treatment for epilepsy and neuropathic pain. Isis has about 5 years of medicinal chemistry experience in designing and synthesizing small molecules for CNS drug applications in academia.

Prior to joining Biohaven, Isis was with Knopp Bioscience, where she worked on the Kv7 channel target platform in lead optimization of small molecule potassium channel activators.

Katherine Sellers, Ph.D., Associate Director, Biology

Katherine Sellers, Ph.D.

Associate Director, Biology

X

Katherine Sellers, Ph.D.

Katherine has over 10 years of biomedical research experience in oncology and immunology. She comes to Biohaven from Rheos Medicines, where she led the Discovery Metabolism Team to identify and prosecute novel metabolic targets for autoimmune and inflammatory diseases. While at Rheos, she co-led two drug discovery pipeline programs, including a successful collaboration target with Roche. Prior to Rheos, Katherine worked across the portfolio within the oncology therapeutic area at Agios Pharmaceuticals, including FDA approved IDH inhibitors.

Katherine’s interests lie in leveraging the therapeutic opportunity afforded by dysregulated metabolism in disease and developing assays and biomarkers to advance drug discovery programs. Katherine was trained as a postdoctoral research fellow at the Francis Crick Institute in London after getting her Ph.D. in Chemistry at the University of Louisville. In both positions she developed an expertise focused on translatable models ranging from human patients, mouse models, organoids and ex vivo tissue slice cultures.

Kelly Piccione, Associate Director, Biology

Kelly Piccione

Associate Director, Biology

Scott Conroy, Research Scientist

Scott Conroy

Research Scientist

Seong Lee, Senior Research Investigator

Seong Lee

Senior Research Investigator